Instability of syllable repetition as a marker of disease progression in Parkinson's disease: A longitudinal study

Movement Disorders

Volumn 26, Issue 1, 2011, Pages 59-64

  Skodda, Sabine ^a   Flasskamp, Andrea ^a   Schlegel, Uwe ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Disease progression; Motor speech performance; Parkinson's disease; Repetitive motor tasks; Speech disorder; Syllable repetition

Indexed keywords

ACCELERATION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; PACE ACCELERATION; PARKINSON DISEASE; PRIORITY JOURNAL; SPEECH; SPEECH DISORDER; SYLLABLE REPETITION; TASK PERFORMANCE; VALIDATION PROCESS;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; DISEASE PROGRESSION; FEMALE; HUMANS; LANGUAGE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; SPEECH DISORDERS; VERBAL BEHAVIOR;

EID: 79951478855     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23382     Document Type: Article

References (34)

1. Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neurology 1998; 51(Suppl. 2): S2-S9.
2. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
3. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-442.
4. Marttila RJ, Rinne UK. Disability and progression in Parkinson's disease. Acta Neurol Scand 1977; 56: 159-169.
5. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med 1993; 328: 176-183.
6. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004; 61: 561-566.
7. Fahn S, Oakes D, Shoulson I, et al. Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498-2508.
8. Hilker R, Schweitzer K, Coburger S, et al. Nonlinear progression of Parkinson's disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F18 activity. Arch Neurol 2005; 62: 378-382.
9. Jankovic J, Kapadia AS. Functional decline in Parkinson's disease. Arch Neurol 2001; 58: 1611-1615.
10. Saiki S, Hirose G, Sakai K, et al. Cardiac 123I-MIBG scintigraphy can assess the disease severity and phenotype of PD. J Neurol Sci 2004; 220: 105-111.
11. Burn DJ, Rowan EN, Allan LM, Molloy S, O'Brien JT, McKeith IG. Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2006; 77: 585-589.
12. Ransmayr G, Kunig G, Neubauer M, Wagner M, Falk M. Effect of age and disease duration on parkinsonian motor scores under levodopa therapy. J Neural Transm Park Dis Dement Sect 1995; 9: 177-188.
13. Baker KK, Ramig LO, Luschei ES, Smith ME. Thyroarytenoid muscle activity associated with hypophonia in Parkinson's disease and aging. Neurology 1998; 51: 1592-1598.
14. Canter GJ. Speech characteristics of patients with Parkinson's disease: I. Intensity, pitch, and duration. J Speech Hear Disord 1963; 28: 221-229.
15. Darley FL, Aronson AE, Brown JR. Clusters of deviant speech dimensions in the dysarthrias. J Speech Hear Res 1969; 12: 462-496.
16. Skodda S, Visser W.Schlegel U. Short- and long-term dopaminergic effects on dysarthria in early Parkinson's disease. J Neural Transm 2010; 117: 197-205.
17. Ho AK, Bradshaw JL, Iansek R. For better or worse: The effect of levodopa on speech in Parkinson's disease. Mov Disord 2008; 23: 575-580.
18. Gamboa J, Jimenez-Jimenez FJ, Nieto A. Acoustic voice analysis in patients with Parkinson's disease treated with dopaminergic drugs. J Voice 1997; 11: 314-320.
19. Goberman AM, Coelho C. Acoustic analysis of parkinsonian speech I: Speech characteristics and L-dopa therapy. NeuroRehabilitation 2002; 17: 237-246.
20. Kompoliti K, Wang QE, Goetz CG, Leurgans S, Raman R. Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease. Neurology 2000; 54: 458-462.
21. Plowman-Prine EK, Okun MS, Sapienza CM, et al. Perceptual characteristics of Parkinsonian speech: a comparison of the pharmacological effects of levodopa across speech and non-speech motor systems. NeuroRehabilitation 2009; 24: 131-144.
22. Muller J, Wenning GK, Verny M, et al. Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. Arch Neurol 2001; 58: 259-264.
23. Benke T, Hohenstein C, Poewe W, Butterworth B. Repetitive speech phenomena in Parkinson's disease. J Neurol Neurosurg Psychiatry 2000; 69: 319-324.
24. Skodda S, Rinsche H, Schlegel U. Progression of dysprosody in Parkinson's disease-a longitudinal study. Mov Disord 2009; 24: 716-722.
25. Skodda S, Flasskamp A, Schlegel U. Instability of syllable repetition as a model for impaired motor processing: is Parkinson's disease a rhythm disorder ? J Neural Transm (in press).
26. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicalpathologic study. Neurology 1992; 42: 1142-1146.
27. Wildgruber D, Ackermann H, Grodd W. Differential contribution of motor cortex, basal ganglia, and cerebellum to speech motor control: effects of syllable repetition rate evaluated by fMRI. Neuroimage 2001; 13: 101-109.
28. Bohland JW, Guenther FH. A fMRI investigation of syllable sequence production. Neuroimage 2006; 32: 821-841.
29. Brendel B, Hertrich I, Erb M, et al. The contribution of mesiofrontal cortex (SMA) to the preparation and execution of repetitive syllable productions: an fMRI study. Neuroimage 2010; 50: 1219-1230.
30. Blin O, Ferrandez AM, Pailhous J, Serratrice G. A new method of quantitative analysis of Parkinsonian gait: report of 6 patients. Rev Neurol (Paris) 2990; 146: 48-50.
31. Morris ME, Iansek R, Matyas TA, Summers JJ. Ability to modulate walking cadence remains intact in Parkinson's disease. JNeurol Neurosurg Psychiatry 1994; 57: 1532-1534.
32. Yahalom G, Simon ES, Thorne R, Peretz C, Giladi N. Hand rhythmic tapping and timing in Parkinson's disease. Parkinsonism Relat Disord 2004; 10: 143-148.
33. Iansek R, Bradshaw JL, Morris ME. Interaction of the basalganglia and supplementary motor area in the elaboration of movements. In: Glencross DJ, Piek JP, editors. Motor control and sensory motor integration: issues and directions. Elsevier Science BV; 1995. p 37-59.
34. Maetzler W, Liepert I, Berg D. Progression of disease in the clinical phase: potential markers. Lancet Neurol 2009; 8: 1158-1171.